Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: A systematic review and meta-analysis

被引：57

作者：

Kobayashi, Tohru ^{[1
,2
]}

Matsuyama, Tasuku ^{[1
,3
]}

Takeuchi, Masanobu ^{[1
]}

Ito, Shinya ^{[1
,4
]}

机构：

[1] Hosp Sick Children, Div Clin Pharmacol & Toxicol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada

[2] Natl Ctr Child Hlth & Dev, Ctr Clin Res & Dev, Dept Dev Strategy, Div Res Planning, Tokyo, Japan

[3] Kyoto Prefectural Univ Med, Dept Emergency Med, Kyoto, Japan

[4] Hosp Sick Children, Motherisk Program, Toronto, ON, Canada

来源：

REPRODUCTIVE TOXICOLOGY | 2016年 / 65卷

关键词：

Serotonin reuptake inhibitors; Autism spectrum disorder; Meta-analysis; Prenatal exposure delayed effect; Child; ANTIDEPRESSANT EXPOSURE; RISK-FACTORS; PREGNANCY; FETAL; DEPRESSION; CHILDREN;

D O I：

10.1016/j.reprotox.2016.07.016

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

To obtain the risk estimates of autism spectrum disorder (ASD) in the offspring exposed to serotonin reuptake inhibitors (SSRI) in utero, we performed systematic review and meta-analysis of relevant studies. Five case-control and three cohort studies were eligible for the analysis. The SSRI group had significantly higher risk of ASD than the SSRI non-exposed group (pooled OR 1.45, 95% CI 1.15-1.82). In the subgroup analyses, however, the risk of ASD was similar between the SSRI group and other antidepressants group (pooled OR 1.14, 95% CI 0.67-1.96). Furthermore, when the analysis was confined to those born to the women with psychiatric disorders, the SSRI group did not show an increased ASD risk (pooled OR 0.96, 95% CI 0.57-1.63) compared to non-exposed groups. In conclusion, SSRI use in pregnancy is associated with an increased risk of ASD in the offspring, but maternal psychiatric condition is a major confounding factor. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：170 / 178

页数：9

共 32 条

[11] Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders [J].